认知行为联合药物治疗精神分裂症疗效分析

Cognitive behavior and medication for schizophrenia

目的分析精神分裂症患者应用认知行为治疗联合利培酮的临床疗效。方法入组80例精神分裂症患者,随机分为利培酮治疗的对照组(40例),利培酮联合认知行为治疗的观察组(40例),通过阳性阴性症状量表(Positive and Negative Syndrome Scale,PANSS)和症状自评量表的评分比较两种方案的疗效。结果与对照组相比,PANSS评分观察组的有效率显著高于对照组;自评量表的结果发现体感觉,强迫症状,人际关系敏感,抑郁,焦虑,敌对,恐怖,偏执,精神病性症状等评分,观察组的评分更低,组间差异有统计学意义(P<0.05)。结论精神分裂症患者应用认知行为治疗联合利培酮治疗的疗效更好,可显著改善患者的临床症状,提示认知行为治疗在治疗精神分裂症患者中具有重要的应用价值。

Objective To analyze the clinical efficacy of cognitive behavioral therapy combined with risperidone in patients with schizophrenia.Methods A total of 80 patients with schizophrenia were randomly divided into risperidone-treated control group(40 cases)and risperidone-combined cognitive-behavioral therapy observation group(40 cases).Positive and Negative Syndrome Scale(PANSS)and Symptom Check List-90(SCL-90)scores were used to compare the efficacy of the two regimens.Results Compared with the control group,the effective rate of PANSS score observation group was significantly higher than that of control group.The results of the self-rating scale showed that the scores of somatosensory,obsessive symptoms,interpersonal sensitivity,depression,anxiety,hostility,terror,paranoia and psychotic symptoms were lower in the observation group,and the difference between groups was statistically significant(P<0.05).Conclusion Cognitive behavioral therapy combined with risperidone can significantly improve the clinical symptoms of patients with schizophrenia,suggesting that cognitive behavioral therapy has important application value in the treatment of schizophrenia patients.